Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting

Ji Ji Young Kim, Ji Hae Han, Geon Park, Young Woo Seo, Cheol-Won Yun, Byung Chul Lee, Jeehyeon Bae, Ae Ran Moon, Tae Hyoung Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The therapeutic efficacy of most anti-cancer drugs depends on their apoptosisinducing abilities. Previously, we showed that a peptide containing the mitochondrial targeting domain (MTD) found in Noxa, a BH-3 only protein of Bcl-2 family, induces necrosis. Here, a fusion peptide of neuropilin-1 (NRP-1) targeting peptide and MTD peptide, designated tumor homing motif 17:MTD (TU17:MTD), was found to induce necrosis in cancer cells in vitro and to cause the regression of tumors when intravenously injected into mice bearing subcutaneous CT26 colorectal carcinoma tumors. The necrosis within tumor tissues was evident upon administering TU17:MTD. TU17:MTD penetrated into tumor cells by targeting to Neuropilin-1, which could be blocked by anti-NRP-1 antibody. The efficacy of TU17:MTD on tumor regression was higher than that of TU17:D(KLAKLAK)2, a fusion peptide of NRP-1 targeting peptide and a pro-apoptotic peptide. The necrotic cell death within tumor tissues was evident at day 1 after administering TU17:MTD systemically. Transplanted subcutaneous substantially reduced in size within two weeks and 5 days, respectively, with no apparent side effects. Together, these results propose that the pro-necrotic peptide MTD may present an alternative approach for development of targeted anti-cancer agents.

Original languageEnglish
Pages (from-to)32449-32461
Number of pages13
JournalOncotarget
Volume7
Issue number22
DOIs
Publication statusPublished - 2016 May 31

Fingerprint

Neuropilins
Neuropilin-1
Necrosis
Peptides
Neoplasms
Colorectal Neoplasms
Noxae

Keywords

  • Mitochondrial targeting domain
  • Necrosis
  • Noxa
  • NRP-1
  • Pro-necrotic peptide

ASJC Scopus subject areas

  • Oncology

Cite this

Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting. / Kim, Ji Ji Young; Han, Ji Hae; Park, Geon; Seo, Young Woo; Yun, Cheol-Won; Lee, Byung Chul; Bae, Jeehyeon; Moon, Ae Ran; Kim, Tae Hyoung.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 32449-32461.

Research output: Contribution to journalArticle

Kim, JJY, Han, JH, Park, G, Seo, YW, Yun, C-W, Lee, BC, Bae, J, Moon, AR & Kim, TH 2016, 'Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting', Oncotarget, vol. 7, no. 22, pp. 32449-32461. https://doi.org/10.18632/oncotarget.8719
Kim, Ji Ji Young ; Han, Ji Hae ; Park, Geon ; Seo, Young Woo ; Yun, Cheol-Won ; Lee, Byung Chul ; Bae, Jeehyeon ; Moon, Ae Ran ; Kim, Tae Hyoung. / Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 32449-32461.
@article{5277964be878469f8ad9c225b33c6602,
title = "Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting",
abstract = "The therapeutic efficacy of most anti-cancer drugs depends on their apoptosisinducing abilities. Previously, we showed that a peptide containing the mitochondrial targeting domain (MTD) found in Noxa, a BH-3 only protein of Bcl-2 family, induces necrosis. Here, a fusion peptide of neuropilin-1 (NRP-1) targeting peptide and MTD peptide, designated tumor homing motif 17:MTD (TU17:MTD), was found to induce necrosis in cancer cells in vitro and to cause the regression of tumors when intravenously injected into mice bearing subcutaneous CT26 colorectal carcinoma tumors. The necrosis within tumor tissues was evident upon administering TU17:MTD. TU17:MTD penetrated into tumor cells by targeting to Neuropilin-1, which could be blocked by anti-NRP-1 antibody. The efficacy of TU17:MTD on tumor regression was higher than that of TU17:D(KLAKLAK)2, a fusion peptide of NRP-1 targeting peptide and a pro-apoptotic peptide. The necrotic cell death within tumor tissues was evident at day 1 after administering TU17:MTD systemically. Transplanted subcutaneous substantially reduced in size within two weeks and 5 days, respectively, with no apparent side effects. Together, these results propose that the pro-necrotic peptide MTD may present an alternative approach for development of targeted anti-cancer agents.",
keywords = "Mitochondrial targeting domain, Necrosis, Noxa, NRP-1, Pro-necrotic peptide",
author = "Kim, {Ji Ji Young} and Han, {Ji Hae} and Geon Park and Seo, {Young Woo} and Cheol-Won Yun and Lee, {Byung Chul} and Jeehyeon Bae and Moon, {Ae Ran} and Kim, {Tae Hyoung}",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.8719",
language = "English",
volume = "7",
pages = "32449--32461",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting

AU - Kim, Ji Ji Young

AU - Han, Ji Hae

AU - Park, Geon

AU - Seo, Young Woo

AU - Yun, Cheol-Won

AU - Lee, Byung Chul

AU - Bae, Jeehyeon

AU - Moon, Ae Ran

AU - Kim, Tae Hyoung

PY - 2016/5/31

Y1 - 2016/5/31

N2 - The therapeutic efficacy of most anti-cancer drugs depends on their apoptosisinducing abilities. Previously, we showed that a peptide containing the mitochondrial targeting domain (MTD) found in Noxa, a BH-3 only protein of Bcl-2 family, induces necrosis. Here, a fusion peptide of neuropilin-1 (NRP-1) targeting peptide and MTD peptide, designated tumor homing motif 17:MTD (TU17:MTD), was found to induce necrosis in cancer cells in vitro and to cause the regression of tumors when intravenously injected into mice bearing subcutaneous CT26 colorectal carcinoma tumors. The necrosis within tumor tissues was evident upon administering TU17:MTD. TU17:MTD penetrated into tumor cells by targeting to Neuropilin-1, which could be blocked by anti-NRP-1 antibody. The efficacy of TU17:MTD on tumor regression was higher than that of TU17:D(KLAKLAK)2, a fusion peptide of NRP-1 targeting peptide and a pro-apoptotic peptide. The necrotic cell death within tumor tissues was evident at day 1 after administering TU17:MTD systemically. Transplanted subcutaneous substantially reduced in size within two weeks and 5 days, respectively, with no apparent side effects. Together, these results propose that the pro-necrotic peptide MTD may present an alternative approach for development of targeted anti-cancer agents.

AB - The therapeutic efficacy of most anti-cancer drugs depends on their apoptosisinducing abilities. Previously, we showed that a peptide containing the mitochondrial targeting domain (MTD) found in Noxa, a BH-3 only protein of Bcl-2 family, induces necrosis. Here, a fusion peptide of neuropilin-1 (NRP-1) targeting peptide and MTD peptide, designated tumor homing motif 17:MTD (TU17:MTD), was found to induce necrosis in cancer cells in vitro and to cause the regression of tumors when intravenously injected into mice bearing subcutaneous CT26 colorectal carcinoma tumors. The necrosis within tumor tissues was evident upon administering TU17:MTD. TU17:MTD penetrated into tumor cells by targeting to Neuropilin-1, which could be blocked by anti-NRP-1 antibody. The efficacy of TU17:MTD on tumor regression was higher than that of TU17:D(KLAKLAK)2, a fusion peptide of NRP-1 targeting peptide and a pro-apoptotic peptide. The necrotic cell death within tumor tissues was evident at day 1 after administering TU17:MTD systemically. Transplanted subcutaneous substantially reduced in size within two weeks and 5 days, respectively, with no apparent side effects. Together, these results propose that the pro-necrotic peptide MTD may present an alternative approach for development of targeted anti-cancer agents.

KW - Mitochondrial targeting domain

KW - Necrosis

KW - Noxa

KW - NRP-1

KW - Pro-necrotic peptide

UR - http://www.scopus.com/inward/record.url?scp=84973530136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973530136&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8719

DO - 10.18632/oncotarget.8719

M3 - Article

C2 - 27083053

AN - SCOPUS:84973530136

VL - 7

SP - 32449

EP - 32461

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -